Subscribe: pubmed: BMT[Jour]
http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=0rkpg7psB96kXSn8rHgLXj86RUVpfN48_gOyRQErBE5
Preview: pubmed: BMT[Jour]

pubmed: BMT[Jour]



NCBI: db=pubmed; Term="Bone marrow transplantation"[Jour]



 



Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome.

Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome.

Bone Marrow Transplant. 2016 Nov 28;:

Authors: Yahng SA, Jeon YW, Yoon JH, Shin SH, Lee SE, Choi YS, Kim DY, Lee JH, Cho BS, Eom KS, Lee S, Min CK, Kim HJ, Lee JW, Lee KH, Min WS, Lee JH, Kim YJ

Abstract
This study aimed to analyze the use of the revised International Prognostic Scoring System (IPSS-R) assessed after hypomethylating treatment (HMT) for patients with myelodysplastic syndrome (MDS) undergoing an allogeneic stem cell transplantation (SCT). Among 115 patients who received pre-SCT HMT, comparison analysis of the prognostic values between the IPSS-R at the time of HMT (IPSS-R@HMT) and at the time of SCT after HMT (IPSS-R@SCT) showed a significantly higher predictive power for overall survival (OS) of the latter. Alteration in IPSS-R risk occurred in 60%, while the patients with 'down-staged' IPSS-R@SCT showed better OS compared with those with 'unchanged' or 'up-staged' risk. On multivariate analysis in all 201 patients, IPSS-R@SCT, monosomal karyotype, treatment failure to pre-SCT treatment, and high hematopoietic cell transplantation-comorbidity index were independently associated with OS. Constructed using these factors, the MDS Transplantation Prognostic Scoring System (MTPSS) identified four risk groups with 4-year OS of 76.4% in low, 61.4% in intermediate-1 and 21.9% in intermediate-2 risk groups, whereas all in the high risk group died within 2 years after SCT (P<0.001). Our study emphasizes the need for further studies aiming to evaluate a transplantation prognostic model such as the MTPSS to make appropriate decisions for transplantation in MDS.Bone Marrow Transplantation advance online publication, 28 November 2016; doi:10.1038/bmt.2016.295.

PMID: 27892952 [PubMed - as supplied by publisher]




Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse.

Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse.

Bone Marrow Transplant. 2016 Nov 28;:

Authors: Gössi F, Spahn M, Zweifel M, Panagiotis S, Mischo A, Stenner F, Hess U, Berthold D, Bargetzi M, Schardt J, Pabst T

PMID: 27892951 [PubMed - as supplied by publisher]




PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation.

PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation.

Bone Marrow Transplant. 2016 Nov 28;:

Authors: Albring JC, Inselmann S, Sauer T, Schliemann C, Altvater B, Kailayangiri S, Rössig C, Hartmann W, Knorrenschild JR, Sohlbach K, Groth C, Lohoff M, Neubauer A, Berdel WE, Burchert A, Stelljes M

PMID: 27892950 [PubMed - as supplied by publisher]




The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis.

The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis.

Bone Marrow Transplant. 2016 Nov 28;:

Authors: Ruutu T, Gratwohl A, Niederwieser D, de Witte T, van der Werf S, van Biezen A, Mohty M, Kröger N, Rambaldi A, McGrath E, Sureda A, Basak G, Greinix H, Duarte RF

Abstract
In 2013, recommendations for a standardized practice in the prophylaxis and treatment of GvHD were adopted and published by the European Society for Blood and Marrow Transplantation and the European LeukemiaNet. One year later, all 341 European Society for Blood and Marrow Transplantation centres performing allogeneic haematopoietic stem cell transplantation were contacted for a change-control analysis and asked to fill in a questionnaire; 111 centres (33%) responded. Of these, 83% had been aware of the recommendations. Paediatric centres (P=0.004), centres with shorter programme duration (P=0.049), not JACIE (the Joint Accreditation Committee of the International Society for Cellular Therapy and the European Society for Blood and Marrow Transplantation)-accredited centres (P=0.010) and centres from middle-income countries (P=0.033) were more likely to be unaware of the recommendations. Thirty-eight per cent of the centres regarded the recommendations as relevant guidelines affecting their policies, 61% as interesting information. Thirty per cent had decided to make changes in their institutional protocols based on the recommendations. More than 80% were willing to use the recommendations for a control arm in randomized studies. This survey shows that the published recommendations had some, though insufficient, impact on the strategies and methods of allogeneic haematopoietic stem cell transplantation applied by the centres. It also identified some of the weaknesses to be addressed when releasing recommendations in the future.Bone Marrow Transplantation advance online publication, 28 November 2016; doi:10.1038/bmt.2016.298.

PMID: 27892949 [PubMed - as supplied by publisher]




Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL).

Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL).

Bone Marrow Transplant. 2016 Nov 28;:

Authors: Shah N, Rauenzahn S, Veltri L, Wen S, Craig M, Hamadani M, Kanate AS, Cumpston A

PMID: 27892948 [PubMed - as supplied by publisher]




Danaparoid reduces the incidence of hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

Danaparoid reduces the incidence of hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

Bone Marrow Transplant. 2016 Nov 28;:

Authors: Machida S, Onizuka M, Toyosaki M, Aoyama Y, Kawai H, Amaki J, Hara R, Ichiki A, Ogawa Y, Kawada H, Ando K

PMID: 27892947 [PubMed - as supplied by publisher]




First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma.

First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma.

Bone Marrow Transplant. 2016 Nov 28;:

Authors: Ghez D, Fortpied C, Mounier N, Carde P, Perrot A, Khaled H, Amorim S, Ramadan S, Bras FL, Erlanson M, Herbaux C, Marolleau JP, Nicolas-Virelezier E, Casasnovas O, Stamatoullas-Bastard A, Fermé C

PMID: 27892946 [PubMed - as supplied by publisher]




Therapy of pediatric ALL relapsing after allogeneic transplant: how to make progress with limited patient numbers?

Therapy of pediatric ALL relapsing after allogeneic transplant: how to make progress with limited patient numbers?

Bone Marrow Transplant. 2016 Nov 28;:

Authors: Bierings M

PMID: 27892945 [PubMed - as supplied by publisher]




Veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic stem cell transplantation: Middle East/North Africa regional consensus on prevention, diagnosis and management.

Veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic stem cell transplantation: Middle East/North Africa regional consensus on prevention, diagnosis and management.

Bone Marrow Transplant. 2016 Nov 28;:

Authors: Al Jefri AH, Abujazar H, Al-Ahmari A, Al Rawas A, Al Zahrani Z, Alhejazi A, Bekadja MA, Ibrahim A, Lahoucine M, Ousia S, Bazarbachi A

Abstract
Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) of the liver is a serious, early complication of haematopoietic stem cell transplantation (HSCT), severe and very severe forms of which are associated with a high mortality rate. A wide variety of patient, disease and treatment-related risk factors for VOD/SOS have been identified. Several bodies have published recommendations for the diagnosis, prevention and management of VOD/SOS following HSCT. A group of regional experts have developed a consensus statement on the diagnosis, prevention and management of VOD/SOS in the Middle East and North Africa region to help in the management of HSCT patients in the region. Risk factors of particular relevance in the region include iron overload in thalassaemia patients, some hereditary metabolic disorders due to consanguinity and infection with hepatitis virus B or C. Recommendations include diagnosis of VOD/SOS based on established clinical criteria, prophylaxis with defibrotide and/or ursodeoxycholic acid in patients at increased risk of VOD/SOS, and treatment with defibrotide for patients with severe/very severe VOD/SOS (and, if clinically indicated, in those with moderate or rapidly progressing VOD/SOS, as per the new European Society for Blood and Marrow Transplantation classification).Bone Marrow Transplantation advance online publication, 28 November 2016; doi:10.1038/bmt.2016.300.

PMID: 27892944 [PubMed - as supplied by publisher]